中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2014年
27期
73-74
,共2页
BIRC5%肝癌%临床病理特征
BIRC5%肝癌%臨床病理特徵
BIRC5%간암%림상병리특정
BIRC5%Hepatocellular carcinoma%Clinicopathological features
目的:探讨凋亡抑制蛋白BIRC5在肝癌中的表达及其表达与临床病理牲的关系。方法免疫组化检测BIRC5在20例正常肝组织及80例肝癌组织中的表达,分析其表达与临床病理特征的关系。结果BIRC5在肝癌组织中的阳性表达率为66.3%,明显高于正常肝组织(5%),差异有统计学意义(P<0.05)。此外,BIRC5在低分化肝细胞癌中的表达率(83.3%)明显高于高-中分化肝细胞癌(55.4%);淋巴结转移患者中BIRC5的表达率(85.7%)明显高于无淋巴结转移患者(55.9%);II-III期患者BIRC5的表达率(83.9%)明显高于I期患者(57.1%),差异有统计学意义(P<0.05);而BIRC5表达率与年龄、性别、肿瘤最大直径无明显相关(P>0.05)。结论BIRC5表达与肝癌的发生密切相关,可能成为肝癌诊断的新型标记物。
目的:探討凋亡抑製蛋白BIRC5在肝癌中的錶達及其錶達與臨床病理牲的關繫。方法免疫組化檢測BIRC5在20例正常肝組織及80例肝癌組織中的錶達,分析其錶達與臨床病理特徵的關繫。結果BIRC5在肝癌組織中的暘性錶達率為66.3%,明顯高于正常肝組織(5%),差異有統計學意義(P<0.05)。此外,BIRC5在低分化肝細胞癌中的錶達率(83.3%)明顯高于高-中分化肝細胞癌(55.4%);淋巴結轉移患者中BIRC5的錶達率(85.7%)明顯高于無淋巴結轉移患者(55.9%);II-III期患者BIRC5的錶達率(83.9%)明顯高于I期患者(57.1%),差異有統計學意義(P<0.05);而BIRC5錶達率與年齡、性彆、腫瘤最大直徑無明顯相關(P>0.05)。結論BIRC5錶達與肝癌的髮生密切相關,可能成為肝癌診斷的新型標記物。
목적:탐토조망억제단백BIRC5재간암중적표체급기표체여림상병리생적관계。방법면역조화검측BIRC5재20례정상간조직급80례간암조직중적표체,분석기표체여림상병리특정적관계。결과BIRC5재간암조직중적양성표체솔위66.3%,명현고우정상간조직(5%),차이유통계학의의(P<0.05)。차외,BIRC5재저분화간세포암중적표체솔(83.3%)명현고우고-중분화간세포암(55.4%);림파결전이환자중BIRC5적표체솔(85.7%)명현고우무림파결전이환자(55.9%);II-III기환자BIRC5적표체솔(83.9%)명현고우I기환자(57.1%),차이유통계학의의(P<0.05);이BIRC5표체솔여년령、성별、종류최대직경무명현상관(P>0.05)。결론BIRC5표체여간암적발생밀절상관,가능성위간암진단적신형표기물。
Objective To investigate the expression of apoptosis inhibitory protein BIRC5 and its relationship with clinicopathologi-cal features in hepatocellular carcinoma (HCC). Methods The expression of BIRC5 was detected in 20 cases of normal liver tissues and 80 cases of hepatocellular carcinoma tissues by immunohistochemistry, then the relationship between BIRC5 expression and clinical pathological features was analyzed. Results The positive rate of BIRC5 expression in HCC was 66.3%, significantly higher than that in the normal liver tissue(5%), with a statistically significant difference(P<0.05). In addition, the expression rate of BIRC5 in poorly differentiated hepatocellular carcinoma (83.3%) was significantly higher than that in well and moderately differentiated hepatocellular carcinoma (55.4%); the expression rate of BIRC5 in patients with lymphatic metastasis(85.7%) was obviously higher than that in patients without lymphatic metastasis(55.9%);the expression rate of BIRC5 in II-III stage of patients (83.9%) was sig-nificantly higher than that in I stage of patients (57.1%), the differences between two groups were statistically significant (P<0.05);moreover, the expression rate of BIRC5 has no significant correlations with age, gender and tumor diameter (P>0.05). Conclusion BIRC5 expression is closely related to the formation of HCC, which may be used as a new diagnostic marker.